Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

Platinum-based chemotherapy remains the cornerstone of treatment for most non-small cell lung cancer (NSCLC) cases either as maintenance therapy or in combination with immunotherapy. However, resistance remains a primary issue. Our findings point to the possibility of exploiting levels of cell divis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kildey, Katrina, Gandhi, Neha S., Sahin, Katherine B., Shah, Esha T., Boittier, Eric, Duijf, Pascal H. G., Molloy, Christopher, Burgess, Joshua T., Beard, Sam, Bolderson, Emma, Suraweera, Amila, Richard, Derek J., O’Byrne, Kenneth J., Adams, Mark N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163776/
https://www.ncbi.nlm.nih.gov/pubmed/34050247
http://dx.doi.org/10.1038/s42003-021-02136-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163776/
https://www.ncbi.nlm.nih.gov/pubmed/34050247
http://dx.doi.org/10.1038/s42003-021-02136-8

Ejemplares similares